Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment
Phase 1/2 Suspended
97 enrolled
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
Phase 1/2 Recruiting
58 enrolled
Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid Tumors
Phase 1/2 Suspended
64 enrolled
Zotiraciclib (TG02) Plus Dose-Dense or Metronomic Temozolomide Followed by Randomized Phase II Trial of Zotiraciclib (TG02) Plus Temozolomide Versus Temozolomide Alone in Adults With Recurrent Anaplastic Astrocytoma and Glioblastoma
Phase 1/2 Terminated
53 enrolled 22 charts
T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery
Phase 1/2 Terminated
12 enrolled 16 charts
Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma
Phase 1/2 Completed
46 enrolled
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
125 enrolled 12 charts
Talazoparib and Temozolomide in Treating Younger Patients With Refractory or Recurrent Malignancies
Phase 1/2 Completed
40 enrolled 32 charts
Gamma-secretase/Notch Signalling Pathway Inhibitor RO4929097 in Combination With Cisplatin, Vinblastine, and Temozolomide in Treating Patients With Recurrent or Metastatic Melanoma
Phase 1/2 Completed
14 enrolled 16 charts
Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Phase 1/2 Completed
118 enrolled 10 charts
Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
Phase 1/2 Completed
112 enrolled 14 charts
Combination Chemotherapy in Treating Patients With Recurrent Glioblastoma Multiforme
Phase 1/2 Unknown
Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma
Phase 1/2 Unknown
58 enrolled